Morton LM, et al. - Researchers performed this population-based study of 700,612 adults in a US cancer data registry, to determine therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) risk after chemotherapy for solid cancer. In addition, they sought to correlate tMDS/AML risk patterns with chemotherapy treatment practices. From the Surveillance, Epidemiology, and End Results (SEER) database, they analyzed 1619 tMDS/AML cases (mean [SD] age, 64.3 [12.2] years; 1148 [70.9%] female). Outcomes suggest statistically significantly elevated tMDS/AML risks after chemotherapy for 22 of 23 solid cancers (all except colon). This highlights the necessity for continued efforts to lessen treatment-related adverse events, especially for solid cancer patients with a favorable prognosis.